Aug 17, 2021 / 08:30PM GMT
Operator
Greetings, and welcome to the Marinus Pharmaceutical's conference call to discuss the top line results of the Phase II tuberous sclerosis complex open-label trial. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) And it is now my pleasure to introduce to your host, Sasha Damouni Ellis, Vice President of Corporate Affairs and Investor Relations. You may begin, Ms. Damouni.
Sasha Damouni Ellis - Marinus Pharmaceuticals, Inc. - VP of Corporate Affairs & IR
Thank you. Please note that the slide presentation for today's call can be accessed within the webcast or by clicking the presentation link, which can be found on the Investors Events and Presentations page of the Marinus website. Before we begin, I would like to remind everyone that some of the statements made today are forward-looking statements under the securities laws. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. These risks and uncertainties are further described in today's press
Marinus Pharmaceuticals Inc Tuberos Sclerosis Complex (TSC) Phase 2 Open Label Data Readout Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
